| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Coherus BioSciences Inc (NASDAQ: CHRS)
CHRS Technical Analysis
5
| As on 9th Jun 2023 CHRS STOCK Price closed @ 5.42 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 10.39 & Strong Sell for SHORT-TERM with Stoploss of 13.50 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CHRSSTOCK Price
| Open | 5.41 | Change | Price | % |
| High | 5.59 | 1 Day | 0.03 | 0.56 |
| Low | 5.36 | 1 Week | 1.33 | 32.52 |
| Close | 5.42 | 1 Month | -1.82 | -25.14 |
| Volume | 2394300 | 1 Year | -12.01 | -68.90 |
| 52 Week High 17.88 | 52 Week Low 4.05 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CHRS Daily Charts |
CHRS Intraday Charts |
Whats New @ Bazaartrend |
CHRS Free Analysis |
|
|
CHRS Important Levels Intraday
| RESISTANCE | 5.86 |
| RESISTANCE | 5.72 |
| RESISTANCE | 5.63 |
| RESISTANCE | 5.55 |
| SUPPORT | 5.29 |
| SUPPORT | 5.21 |
| SUPPORT | 5.12 |
| SUPPORT | 4.98 |
CHRS Forecast May 2024
| 4th UP Forecast | 13.09 |
| 3rd UP Forecast | 10.63 |
| 2nd UP Forecast | 9.11 |
| 1st UP Forecast | 7.59 |
| 1st DOWN Forecast | 3.25 |
| 2nd DOWN Forecast | 1.73 |
| 3rd DOWN Forecast | 0.21 |
| 4th DOWN Forecast | -2.25 |
CHRS Weekly Forecast
| 4th UP Forecast | 9.47 |
| 3rd UP Forecast | 8.17 |
| 2nd UP Forecast | 7.37 |
| 1st UP Forecast | 6.56 |
| 1st DOWN Forecast | 4.28 |
| 2nd DOWN Forecast | 3.47 |
| 3rd DOWN Forecast | 2.67 |
| 4th DOWN Forecast | 1.37 |
CHRS Forecast2024
| 4th UP Forecast | 33.07 |
| 3rd UP Forecast | 24.2 |
| 2nd UP Forecast | 18.72 |
| 1st UP Forecast | 13.24 |
| 1st DOWN Forecast | -2.4 |
| 2nd DOWN Forecast | -7.88 |
| 3rd DOWN Forecast | -13.36 |
| 4th DOWN Forecast | -22.23 |
Coherus BioSciences Inc ( NASDAQ USA Symbol : CHRS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CHRS Business Profile
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service